PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
PVCT was delisted on the 13th of October, 2016.
8 hedge funds and large institutions have $4K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 35 closing their positions.
80% less funds holding
Funds holding: 41 → 8 (-33)
94% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 35
100% less capital invested
Capital invested by funds: $1.05M → $4K (-$1.04M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$366K |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$221K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$107K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$81K |
| 5 |
Renaissance Technologies
New York
|
-$80K |
PVCT Hedge Fund Activity: Q4 2016 in Review
8 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q4 2016, worth a combined $4K — down 100% from $1.05M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of PVCT and 2 opened new positions — a net loss of 33 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $366K sold.
- 8 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q4 2016, down from 41 in Q3 2016.
- Funds reported $4K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q4 2016, down 100% quarter-over-quarter.
- 2 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q4 2016 and 35 closed out, a net change of -33 holders.
- The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) seller in Q4 2016 was Vanguard Group, an estimated $366K sold.
Based on aggregated 13F filings for Q4 2016.